Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

AVEO PHARMA Form 4 May 17, 2016	CEUTICALS IN	C							
								OMB A	PROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMI Washington, D.C. 20549				COMMISSION	OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	STATEMENT Filed pursuant Section 17(a) of 30	T OF CHAN	GES IN I SECUR	BENEFI ITIES e Securitie ling Com	C IAI es Ex pany	chang Act of	e Act of 1934, f 1935 or Section	Expires: Estimated a burden hou response	rs per
(Print or Type Respon	ises)								
BAILEY MICHAEL P Symbol			Name and Ticker or Trading PHARMACEUTICALS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (I C/O AVEO PHA INC., ONE BRO FLOOR		(Month/D	-	ansaction			X Director X Officer (give below) Pres		Owner er (specify
(5	Street)	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
CAMBRIDGE, N	AA 02142						Form filed by M Person	fore than One Re	porting
(City) (S	State) (Zip)	Tabl	e I - Non-De	erivative S	ecurit	ies Aco	uired, Disposed of	, or Beneficial	lv Owned
Security (Mor (Instr. 3)	ransaction Date 2A. nth/Day/Year) Exe any (Mo	Deemed cution Date, if	3.	4. Securiti on(A) or Dis (D) (Instr. 3, 4	ies Ac sposed	quired of	5. Amount of Securities Beneficially Owned		7. Nature of
Common 05/1 Stock	13/2016		А	51,813	А	<u>(1)</u>	68,848	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	erivative Expiration Date ecurities (Month/Day/Year) cquired (A) r Disposed of D) nstr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. P Deri Secu (Ins
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Common Stock Warrants (right to buy)	\$ 1	05/13/2016		A	51,813	(2)	<u>(3)</u>	Common Stock	51,813	

Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BAILEY MICHAEL P C/O AVEO PHARMACEUTICALS, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE, MA 02142	Х		President & CEO			

Signatures

/s/ Michael	
Bailey	05/17/2016
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported securities are included within 51,813 Units purchased by the reporting person for \$0.965 per Unit. Each Unit consists of one (1) share of common stock and one warrant to purchase one share of common stock.
- (2) The warrants are immediately exercisable upon issuance.
- (3) The warrants expire five years from their date of issuance.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.